References

Single-Dose psilocybin treatment for major depressive disorder: a randomized clinical trial

10.1001/jama.2023.14530 · ExternalCitation · doi-reference

Single treatment With MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial

10.1001/jama.2025.13481 · ExternalCitation · doi-reference

Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial

10.1001/jamapsychiatry.2020.3285 · ExternalCitation · doi-reference

Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial

10.1001/jamapsychiatry.2022.2096 · ExternalCitation · doi-reference

Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial

10.1001/jamapsychiatry.2023.4685 · ExternalCitation · doi-reference

Adverse events in studies of classic psychedelics: a systematic review and meta-analysis

10.1001/jamapsychiatry.2024.2546 · ExternalCitation · doi-reference

Efficacy and safety of psilocybin in treatment-resistant major depression: the EPISODE randomized clinical trial

10.1001/jamapsychiatry.2026.0132 · ExternalCitation · doi-reference

Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms

10.1002/ajmg.b.30197 · ExternalCitation · doi-reference

Therapeutic frameworks in integration sessions in substance-assisted psychotherapy: A systematic review

10.1002/cpp.2945 · ExternalCitation · doi-reference

Risk factors and comorbidity of ICD-11 PTSD and complex PTSD: findings from a trauma-exposed population based sample of adults in the United Kingdom

10.1002/da.22934 · ExternalCitation · doi-reference

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

10.1007/s00213-006-0457-5 · ExternalCitation · doi-reference

LSD enhances suggestibility in healthy volunteers

10.1007/s00213-014-3714-z · ExternalCitation · doi-reference

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

10.1007/s00213-017-4771-x · ExternalCitation · doi-reference

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

10.1007/s00213-020-05692-9 · ExternalCitation · doi-reference

Suicidal ideation, clinical worsening and outcomes among child participants in trauma-focused treatment

10.1007/s10802-024-01242-5 · ExternalCitation · doi-reference

Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors

10.1016/j.biopsych.2012.04.005 · ExternalCitation · doi-reference

Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

10.1016/j.biopsych.2014.04.010 · ExternalCitation · doi-reference

Acute effects of lysergic acid diethylamide in healthy subjects

10.1016/j.biopsych.2014.11.015 · ExternalCitation · doi-reference

Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study

10.1016/j.biopsych.2022.08.025 · ExternalCitation · doi-reference

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study

10.1016/j.eclinm.2020.100538 · ExternalCitation · doi-reference

Psychedelic-augmented psychotherapy for overcoming traumatic dissociation: a review of neuroscientific and phenomenological evidence

10.1016/j.ejtd.2024.100431 · ExternalCitation · doi-reference

Efficacité des psychédéliques en psychiatrie, une revue systématique

10.1016/j.encep.2020.12.002 · ExternalCitation · doi-reference

Immune-related biomarkers and suicidal behaviors: a meta-analysis

10.1016/j.euroneuro.2023.05.009 · ExternalCitation · doi-reference

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

10.1016/j.jad.2023.01.073 · ExternalCitation · doi-reference

The need for establishing best practices and gold standards in psychedelic medicine

10.1016/j.jad.2023.03.083 · ExternalCitation · doi-reference

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

10.1016/j.jad.2023.04.105 · ExternalCitation · doi-reference

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – a first-in-kind open-label pilot study

10.1016/j.jad.2024.09.133 · ExternalCitation · doi-reference

Psychedelic experiences and finitude in serious Illness: a qualitative synthesis

10.1016/j.jpainsymman.2026.03.012 · ExternalCitation · doi-reference

Behaviorally-indexed distress tolerance and suicidality

10.1016/j.jpsychires.2012.02.015 · ExternalCitation · doi-reference

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

10.1016/j.medj.2024.01.005 · ExternalCitation · doi-reference

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial

10.1016/j.medj.2025.100725 · ExternalCitation · doi-reference

Storm on predictive brain: a neurocomputational account of ketamine antidepressant effect

10.1016/j.neubiorev.2023.105410 · ExternalCitation · doi-reference

The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis

10.1016/j.neubiorev.2025.106086 · ExternalCitation · doi-reference

Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A

10.1016/j.neuroscience.2008.11.036 · ExternalCitation · doi-reference

Hallucinogens

10.1016/j.pharmthera.2003.11.002 · ExternalCitation · doi-reference

Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review

10.1016/j.psychres.2024.115880 · ExternalCitation · doi-reference

Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report

10.1016/j.psychres.2025.116381 · ExternalCitation · doi-reference

Suicide after psychedelic-assisted treatment in context

10.1016/j.psychres.2025.116399 · ExternalCitation · doi-reference

A scoping review of variations in psychedelic interventions for psychological suffering associated with the end of life

10.1016/j.socscimed.2025.118536 · ExternalCitation · doi-reference

Suicidal crisis: first regulatory approval of IV racemic ketamine

10.1016/s0140-6736(26)00594-5 · ExternalCitation · doi-reference

How do antidepressants work? New perspectives for refining future treatment approaches

10.1016/s2215-0366(17)30015-9 · ExternalCitation · doi-reference

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

10.1017/s0033291718001356 · ExternalCitation · doi-reference

Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer

10.1021/acsptsci.1c00020 · ExternalCitation · doi-reference

On the relationship between classic psychedelics and suicidality: a systematic review

10.1021/acsptsci.1c00024 · ExternalCitation · doi-reference

The interpersonal theory of suicide

10.1037/a0018697 · ExternalCitation · doi-reference

The molecular bases of the suicidal brain

10.1038/nrn3839 · ExternalCitation · doi-reference

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

10.1038/s41386-023-01648-7 · ExternalCitation · doi-reference

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

10.1038/s41386-025-02091-6 · ExternalCitation · doi-reference

Altered anterior cingulate glutamatergic metabolism in depressed adolescents with current suicidal ideation

10.1038/s41398-020-0792-z · ExternalCitation · doi-reference

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

10.1038/s41398-021-01706-y · ExternalCitation · doi-reference

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses

10.1038/s41398-025-03410-7 · ExternalCitation · doi-reference

Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom?

10.1038/s41537-025-00700-3 · ExternalCitation · doi-reference

A neuroscientific model of near-death experiences

10.1038/s41582-025-01072-z · ExternalCitation · doi-reference

Psychedelics reopen the social reward learning critical period

10.1038/s41586-023-06204-3 · ExternalCitation · doi-reference

Psilocybin desynchronizes the human brain

10.1038/s41586-024-07624-5 · ExternalCitation · doi-reference

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

10.1038/s41591-023-02455-9 · ExternalCitation · doi-reference

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial

10.1038/s41591-025-04154-z · ExternalCitation · doi-reference

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

10.1038/s41593-023-01316-5 · ExternalCitation · doi-reference

Psychedelics alter metaphysical beliefs

10.1038/s41598-021-01209-2 · ExternalCitation · doi-reference

Case analysis of long-term negative psychological responses to psychedelics

10.1038/s41598-023-41145-x · ExternalCitation · doi-reference

Strategies for resolving challenging psychedelic experiences: Insights from a mixed-methods study

10.1038/s41598-024-79931-w · ExternalCitation · doi-reference

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

10.1038/s41598-025-26198-4 · ExternalCitation · doi-reference

An Integrated theory of false insights and beliefs under psychedelics

10.1038/s44271-024-00120-6 · ExternalCitation · doi-reference

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

10.1038/tp.2017.54 · ExternalCitation · doi-reference

Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports

10.1055/a-1524-2794 · ExternalCitation · doi-reference

Trial of psilocybin versus escitalopram for depression

10.1056/nejmoa2032994 · ExternalCitation · doi-reference

Single-dose psilocybin for a treatment-resistant episode of major depression

10.1056/nejmoa2206443 · ExternalCitation · doi-reference

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

10.1073/pnas.1119598109 · ExternalCitation · doi-reference

Therapeutic-like context and relational support during psychedelic use moderate links among stress, challenging experiences, and psychological outcomes

10.1080/02791072.2026.2644857 · ExternalCitation · doi-reference

Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder

10.1080/10401230601163451 · ExternalCitation · doi-reference

PTSD symptoms, suicidal ideation, and suicide risk in university students: the role of distress tolerance

10.1080/10926771.2019.1709594 · ExternalCitation · doi-reference

Which near-death experience features are associated with reduced fear of death?

10.1080/13576275.2021.2017868 · ExternalCitation · doi-reference

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series

10.1080/20008066.2025.2609425 · ExternalCitation · doi-reference

Matthew oram. the trials of psychedelic therapy: LSD psychotherapy in America

10.1093/ahr/rhaa270 · ExternalCitation · doi-reference

Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants

10.1093/ijnp/pyaa087 · ExternalCitation · doi-reference

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study

10.1097/jcp.0000000000000436 · ExternalCitation · doi-reference

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

10.1097/nmd.0000000000000113 · ExternalCitation · doi-reference

Risk factors for early recurrence after discontinuing lithium in bipolar disorder

10.1111/bdi.13206 · ExternalCitation · doi-reference

The importance of high distress tolerance in the relationship between nonsuicidal self-injury and suicide potential

10.1111/sltb.12048 · ExternalCitation · doi-reference

Psychedelics

10.1124/pr.115.011478 · ExternalCitation · doi-reference

REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics

10.1124/pr.118.017160 · ExternalCitation · doi-reference

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial

10.1136/bmj-2021-067194 · ExternalCitation · doi-reference

Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting

10.1136/bmjopen-2017-016025 · ExternalCitation · doi-reference

Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims

10.1176/appi.ajp.159.3.419 · ExternalCitation · doi-reference

Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study

10.1176/appi.ajp.2018.17060720 · ExternalCitation · doi-reference

Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression

10.1176/appi.ajp.20230890 · ExternalCitation · doi-reference

The safety of psilocybin-assisted psychotherapy: a systematic review

10.1177/00048674241289024 · ExternalCitation · doi-reference

Psychedelic Psychotherapy: Insights From 25 Years of Research

10.1177/0022167816670996 · ExternalCitation · doi-reference

The psychological correlates of decreased death anxiety after a near-death experience: the role of self-esteem, mindfulness, and death representations

10.1177/0022167819892107 · ExternalCitation · doi-reference

The mediating roles of affect lability and experiential avoidance between distress tolerance and suicidal ideation among college students

10.1177/00332941231216671 · ExternalCitation · doi-reference

Human hallucinogen research: guidelines for safety

10.1177/0269881108093587 · ExternalCitation · doi-reference

Pilot study of the 5-HT2A R agonist psilocybin in the treatment of tobacco addiction

10.1177/0269881114548296 · ExternalCitation · doi-reference

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

10.1177/0269881114565144 · ExternalCitation · doi-reference

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

10.1177/0269881114565653 · ExternalCitation · doi-reference

Psychedelics not linked to mental health problems or suicidal behavior: a population study

10.1177/0269881114568039 · ExternalCitation · doi-reference

Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences

10.1177/0269881116662634 · ExternalCitation · doi-reference

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

10.1177/0269881116675512 · ExternalCitation · doi-reference

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial

10.1177/0269881116675513 · ExternalCitation · doi-reference

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women

10.1177/0269881118798610 · ExternalCitation · doi-reference

Pivotal mental states

10.1177/0269881120959637 · ExternalCitation · doi-reference

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review

10.1177/02698811221116926 · ExternalCitation · doi-reference

Belief changes associated with psychedelic use

10.1177/02698811221131989 · ExternalCitation · doi-reference

Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial

10.1177/02698811231154852 · ExternalCitation · doi-reference

Drug-drug interactions involving classic psychedelics: a systematic review

10.1177/02698811231211219 · ExternalCitation · doi-reference

Psychiatric risks for worsened mental health after psychedelic use

10.1177/02698811241232548 · ExternalCitation · doi-reference

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants

10.1177/02698811241246857 · ExternalCitation · doi-reference

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression

10.1177/02698811251346697 · ExternalCitation · doi-reference

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder

10.1177/02698811261424214 · ExternalCitation · doi-reference

The neurobiology of suicide and suicidality

10.1177/070674370304800504 · ExternalCitation · doi-reference

History repeating: Guidelines to address common problems in psychedelic science

10.1177/20451253231198466 · ExternalCitation · doi-reference

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis

10.1177/20451253251372449 · ExternalCitation · doi-reference

A continuum hypothesis of psychotomimetic rapid antidepressants

10.1177/23982128211007772 · ExternalCitation · doi-reference

Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans

10.1177/2470547020939564 · ExternalCitation · doi-reference

Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report

10.1186/s12888-024-06303-z · ExternalCitation · doi-reference

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant’s experience

10.1192/bjo.2024.768 · ExternalCitation · doi-reference

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

10.1371/journal.pone.0012412 · ExternalCitation · doi-reference

The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network

10.1371/journal.pone.0118143 · ExternalCitation · doi-reference

Survey of subjective ‘God encounter experiences’: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT

10.1371/journal.pone.0214377 · ExternalCitation · doi-reference

Extended difficulties following the use of psychedelic drugs: a mixed methods study

10.1371/journal.pone.0293349 · ExternalCitation · doi-reference

Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences

10.1371/journal.pone.0322501 · ExternalCitation · doi-reference

The three-step theory (3ST): a new theory of suicide rooted in the “ideation-to-action” framework

10.1521/ijct.2015.8.2.114 · ExternalCitation · doi-reference

Broadband cortical desynchronization underlies the human psychedelic state

10.1523/jneurosci.2063-13.2013 · ExternalCitation · doi-reference

Looking for the self: phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution

10.3389/fnhum.2017.00245 · ExternalCitation · doi-reference

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

10.3389/fphar.2017.00974 · ExternalCitation · doi-reference

Predicting responses to psychedelics: a prospective study

10.3389/fphar.2018.00897 · ExternalCitation · doi-reference

The impact of ayahuasca on suicidality: results from a randomized controlled trial

10.3389/fphar.2019.01325 · ExternalCitation · doi-reference

DMT models the near-death experience

10.3389/fpsyg.2018.01424 · ExternalCitation · doi-reference

History of the administration of psychedelics in France

10.3389/fpsyg.2023.1131565 · ExternalCitation · doi-reference

Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use

10.3389/fpsyg.2025.1528253 · ExternalCitation · doi-reference

Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics

10.3389/fpsyt.2019.00896 · ExternalCitation · doi-reference

Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation

10.3389/fpsyt.2020.00782 · ExternalCitation · doi-reference

How psychedelic-assisted treatment works in the bayesian brain

10.3389/fpsyt.2022.812180 · ExternalCitation · doi-reference

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

10.3389/fpsyt.2023.1133414 · ExternalCitation · doi-reference

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

10.3389/fpsyt.2023.1271152 · ExternalCitation · doi-reference

Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials

10.3389/fpsyt.2024.1359088 · ExternalCitation · doi-reference

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials

10.3389/fpsyt.2024.1477996 · ExternalCitation · doi-reference

The association between experiential avoidance, depressive symptoms, and suicidal ideation in hospitalized older adults with functional impairments: the moderating role of resilience

10.3389/fpsyt.2025.1739518 · ExternalCitation · doi-reference

Psychedelics and suicide-related outcomes: a systematic review

10.3390/jcm14051416 · ExternalCitation · doi-reference

Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors

10.3390/ph14121213 · ExternalCitation · doi-reference

Multimodal examination of distress tolerance and suicidality in acute-care psychiatric inpatients

10.5127/jep.059416 · ExternalCitation · doi-reference

Experiential avoidance process model: a review of the mechanism for the generation and maintenance of avoidance behavior

10.5152/pcp.2024.23777 · ExternalCitation · doi-reference

Le traitement médiatique du LSD en France en 1966: de la panique morale à la fin des études cliniques

10.7202/1091460ar · ExternalCitation · doi-reference

U.S. psychedelic use and microdosing in 2025: insights from a probability-based and nationally representative survey

10.7249/rhq-13-03-02 · ExternalCitation · doi-reference